Skip to main content
Dechra Pharmaceuticals PLC logo

Dechra Pharmaceuticals PLC — Investor Relations & Filings

Ticker · DPH ISIN · US2434351043 LEI · 213800J4UVB5OWG8VX82 IL Manufacturing
Open in API
Filings indexed 1,018 across all filing types
Latest filing 2019-09-17 Regulatory Filings
Country GB United Kingdom
Listing IL DPH

About Dechra Pharmaceuticals PLC

https://www.dechra.com/

Dechra Pharmaceuticals PLC is a global specialist business focused on veterinary pharmaceuticals and related products. The company's expertise encompasses the development, manufacture, marketing, and sale of high-quality veterinary medicines. Its product portfolio includes both novel and differentiated generic pharmaceuticals, with a significant focus on products for companion animals. Dechra provides solutions and support to veterinary professionals worldwide to improve animal health and welfare.

Recent filings

Filing Released Lang Actions
Annual Financial Report
Regulatory Filings Classification · 98% confidence The document is very short (2569 characters) and explicitly states that the 'Annual Report and Accounts', 'Notice of Annual General Meeting', and 'Proxy Form' have been 'mailed to shareholders' and 'submitted to the National Storage Mechanism'. It is not the full report itself, but an announcement about the publication and availability of several key documents, including the AGM notice and the Annual Report. Since it announces the release of reports and is filed via RNS, the most appropriate classification based on the 'MENU VS MEAL' rule is Report Publication Announcement (RPA). It also contains an RNS Number and is clearly a regulatory news service announcement.
2019-09-17 English
Block listing Interim Review
Share Issue/Capital Change Classification · 99% confidence The document is explicitly labeled as an 'RNS Number' and contains multiple sections titled 'BLOCK LISTING SIX MONTHLY RETURN' dated 16 September 2019, covering a six-month period (March 15, 2019, to September 14, 2019). This format, originating from RNS (the news service of the London Stock Exchange) and detailing security movements under various schemes, is a specific type of regulatory disclosure. Since it is a direct, structured regulatory announcement rather than a general company report or a mere announcement of a report's publication, the most appropriate classification is 'Regulatory Filings' (RNS), as it represents a mandatory filing to the exchange.
2019-09-16 English
Opening of its solar power plant in Croatia & CMD
Environmental & Social Information Classification · 99% confidence The document begins with an 'RNS Number' and is dated September 11, 2019. It announces the official opening of a new solar-powered facility in Croatia, detailing the investment cost, environmental impact (CO2 reduction), and strategic benefits. The content is a general corporate announcement regarding an operational milestone and investment, not a formal financial report (like 10-K or IR) or a specific regulatory filing like insider trading (DIRS) or dividend notice (DIV). The presence of the RNS number and the nature of the announcement strongly suggest it is a general regulatory news service release. Since it is a general announcement that doesn't fit the more specific categories (like ER, CT, CAP, etc.), the most appropriate fallback category is Regulatory Filings (RNS). The document length is relatively short (under 5,000 characters) and functions as a news release.
2019-09-11 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is identified by the 'RNS Number' header and explicitly states it is a 'Notification and public disclosure of transactions by persons discharging managerial responsibilities (PDMRs)'. It details the granting of share awards (LTIP) to Directors (Ian Page and Tony Griffin) and includes the required 'Notification of Dealing Form' structure mandated by regulations like the EU Market Abuse Regulation. This content directly corresponds to the definition of Director's Dealing (insider trades by management).
2019-09-06 English
Availability of the 2019 Annual Report
Report Publication Announcement Classification · 98% confidence The document is a short announcement (2135 chars) published via RNS (RNS Number : 2332L) from Dechra Pharmaceuticals PLC. The core purpose of the text is to announce the 'Availability of 2019 Annual Report and Accounts' and state that the documents (Annual Report, Notice of AGM, Proxy Form) 'are scheduled to be mailed' and will be submitted to the National Storage Mechanism. According to Rule 2 (The 'MENU VS MEAL' Rule), when a document announces the publication or availability of a report rather than containing the full report itself, it should be classified as a Report Publication Announcement (RPA). Although it mentions the AGM documents, the primary action is announcing the availability of the reports.
2019-09-04 English
Audited preliminary results - year ended 30.6.19
Earnings Release Classification · 100% confidence The document is titled 'Preliminary Results Announcement' and provides detailed financial highlights, including Revenue, Operating Profit, EPS, and Dividend for the year ended 30 June 2019. It contains a comprehensive 'Financial Summary' table comparing 2019 results to 2018, and a 'Chief Executive Officer's Statement' discussing segment performance and product development. This structure is characteristic of an official annual financial disclosure. Although it mentions being 'audited preliminary results' and is distributed via RNS (RNS Number : 7978K), the content itself is the full annual performance report, not just an announcement of its publication. Therefore, it aligns best with the Annual Report category (10-K), which covers full yearly performance, even if the specific regulatory filing might be a local equivalent or a preliminary version thereof. FY 2019
2019-09-02 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.